Overall, our study highlights the role of COPA in regulating erdafitinib resistance, and provides a promising therapeutic target to enhance the sensitivity of erdafitinib treatment in FGFR‐altered bladder cancer. This evidence concerns the gene COPA and urinary bladder cancer.